Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Mantle Cell Lymphoma Clinical Trial

Official title:

Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01460602
• Other study ID #: X05266
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: May 2010
• Est. completion date: October 2014

Study information

• Verified date: July 2020
• Source: Louisiana State University Health Sciences Center Shreveport
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan (rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma.

Description:

Number of Subjects: During the Phase 1 part of the study as many as 15 subjects may be enrolled, based on the dose escalation scheme; the actual number of subjects enrolled will depend on the dose level at which the maximum tolerated dose (MTD) is established.

During the Phase 2 part of the study, approximately 15 subjects will be enrolled in order to obtain a total 30 response-evaluable subjects.

Study Objectives:

The primary objectives of this study are:

• Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy.

The secondary objectives of this study are to:

• Determine the MTD of VELCADE and Nipent in combination with Rituxan (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy

• Evaluate the safety and tolerability of VNR

• Determine the time to response

• Determine duration of response

• Determine the time to progression (TTP)

• Determine the progression free survival (PFS) rate

• Determine the 1-year survival

• Determine overall survival (OS)

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Voluntary written informed consent.

2. Male or female subject 18 years of age and older

3. Karnofsky Performance Status (KPS) score of 50%. ECOG Performance Status score greater than 2.

4. Histologically confirmed follicular Grade 1-3a, marginal zone or mantle cell NHL.

5. Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.

6. Bi-dimensionally measurable disease with at least 1 lesion 2 cm in a single dimension

7. Hematologic, hepatic, and renal function parameters.

8. Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs

9. Expected survival of 3 months

10. Accepted birth control methods during treatment and for 12 months after completion of treatment.

Exclusion Criteria:

1. Follicular lymphoma Grade 3b

2. History of allergy to any of the study medications, their analogues, murine proteins, or excipients in the various formulations

3. Grade 2 peripheral neuropathy or clinical examination within 14 days before enrollment

4. Serum creatinine 2.5 mg/dL within 14 days before enrollment.

5. Absolute neutrophil count (ANC) < 1,000/L, platelet count < 70,000/L within 14 days before enrollment

6. Aspartate transaminase (AST [SGOT]) and alanine transaminase (ALT/SGPT]) > 2 x the upper limit of normal (ULN), total bilirubin > 3 ULN

7. Rituxan refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior Rituxan or prior Rituxan-containing regimen, or a response with a TTP of less than 6 months)

8. Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosurea or mytomycin-C)

9. Prior lymphoma vaccine therapy within 12 months to Study Day 1

10. Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1

11. Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1

12. Known history of hepatitis or hepatic disease.

13. Presence of central nervous system (CNS) lymphoma

14. Known history of HIV infection or AIDS

15. Histologic transformation (Follicular or Marginal zone to diffuse large B cell lymphoma [DLBCL]

16. Presence of pleural or peritoneal effusion with positive cytology for lymphoma

17. Another primary malignancy requiring active treatment

18. Serious non-malignant disease (e.g., congestive heart failure [CHF], hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions (including psychiatric), which would compromise protocol objectives n the opinion of the Investigator and/or Sponsor

19. New York Heart Association Class III or IV (Appendix D) cardiac disease

20. Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1

21. Female subject who is pregnant or currently breast-feeding

22. Received other investigational drugs with 14 days before enrollment

23. Hypersensitivity to bortezomib, pentostatin, rituximab, boron or mannitol.

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Intervention

Drug:
• MTD of Velcade, Nipent and Rituxan established in Part 1
One of the following dose levels will be chosen and used in Part 2: (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1 (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1 (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1 (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1

Locations

Country	Name	City	State
United States	LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center	Shreveport	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Louisiana State University Health Sciences Center Shreveport	Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy	Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48	up to 48 months
Primary	ORR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy	Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48	up to 48 months
Secondary	Maximum Tolerated Dose	Number of participants with adverse events as a measure of safety and tolerability	Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48
Secondary	Rate of progression of disease	Summary data on time to progression of disease of study subjects	Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48